Aroa Biosurgery (ASX:ARX) FCF Margin % : -18.06% (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Aroa Biosurgery FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Aroa Biosurgery's Free Cash Flow for the six months ended in Sep. 2024 was A$-6.48 Mil. Aroa Biosurgery's Revenue for the six months ended in Sep. 2024 was A$35.91 Mil. Therefore, Aroa Biosurgery's FCF Margin % for the quarter that ended in Sep. 2024 was -18.06%.

As of today, Aroa Biosurgery's current FCF Yield % is -7.34%.

The historical rank and industry rank for Aroa Biosurgery's FCF Margin % or its related term are showing as below:

ASX:ARX' s FCF Margin % Range Over the Past 10 Years
Min: -41.31 Med: -24.96 Max: -14.09
Current: -14.09

During the past 5 years, the highest FCF Margin % of Aroa Biosurgery was -14.09%. The lowest was -41.31%. And the median was -24.96%.

ASX:ARX's FCF Margin % is ranked worse than
61.54% of 819 companies
in the Medical Devices & Instruments industry
Industry Median: -3.57 vs ASX:ARX: -14.09

Aroa Biosurgery FCF Margin % Historical Data

The historical data trend for Aroa Biosurgery's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aroa Biosurgery FCF Margin % Chart

Aroa Biosurgery Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Mar24

FCF Margin %

-29.13

-41.31

-17.97

-20.79

Aroa Biosurgery Semi-Annual Data
	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24	Sep24
FCF Margin %	Get a 7-Day Free Trial					-24.05	-13.41	-33.66	-9.94	-18.06

Competitive Comparison of Aroa Biosurgery's FCF Margin %

For the Medical Devices subindustry, Aroa Biosurgery's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aroa Biosurgery's FCF Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Aroa Biosurgery's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Aroa Biosurgery's FCF Margin % falls into.

Save Embed

;

Save Embed

;

Aroa Biosurgery FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Aroa Biosurgery's FCF Margin for the fiscal year that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Mar. 2024 )	/	Revenue (A: Mar. 2024 )
	=	-13.173	/	63.357
	=	-20.79 %

Aroa Biosurgery's FCF Margin for the quarter that ended in Sep. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2024 )	/	Revenue (Q: Sep. 2024 )
	=	-6.484	/	35.907
	=	-18.06 %

Aroa Biosurgery FCF Margin % Related Terms

Thank you for viewing the detailed overview of Aroa Biosurgery's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Aroa Biosurgery Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Aroa Biosurgery Ltd (ASX:ARX) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

AROAF:USA

Address

64 Richard Pearse Drive, Mangere, Airport Oaks, Auckland, NZL, 2022

Website

https://www.aroa.com

Aroa Biosurgery Ltd is a soft tissue regeneration company that develops, manufactures and sells medical devices for wound and soft tissue repair using its proprietary extracellular matrix (ECM) technology. It is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. The Company is in the business of developing, manufacturing and selling soft tissue repair products. The company's principal market is the United States where it has five key products for sale targeting chronic wounds, hernia, plastics, reconstructive surgery and trauma/limb salvage/tumor surgery.

Aroa Biosurgery Headlines

No Headlines